Level of Serum Amyloid A in Patients with Chronic Kidney Disease
Chronic kidney disease (CKD) threatens individuals and healthcare systems worldwide. Chronic kidney disease indicators include urea, creatinine, GPT, GOT, and serum amyloid A. The relationship between serum amyloid E and chronic kidney disease and its relationship to the development and severity of the disease. In a case-control study, 25 samples were collected from people with chronic kidney disease at Al-Kadhimiya Teaching Hospital, and 25 samples were collected from healthy people of the same age and gender who were in good health. The immunochemical measurement technique was used to determine serum amyloid A levels. Urea, creatinine, GOT, and GPT levels were determined using a colorimetric assay by spectrophotometer. The study was carried out between 2022 and 2023. The results showed that there was no statistical significance in age. While urea and creatinine levels were high in all age groups included in the study. While the results of GOT and GPT were low in all groups of patients, except for GOT in the age group from 20 to 39 years, where there was no statistical significance. In conclusion, serum amyloid A levels were high in all groups compared to the control group. The non-statistically significant results with respect to age, along with the marked decline in liver function levels, the apparent increase in urea and creatinine levels, as well as the strikingly high serum amyloid A protein concentrations in the group of patients suffering from chronic kidney disease, indicate the importance of the role Serum amyloid A protein plays an important indicator in diagnosing the severity of the disease.